[The pharmacological blockade of protein glycosylation in diabetes mellitus using sulfonylurea derivatives and biguanides].
A hypothesis is advanced, according to which substances containing an amino group can compete with glucose in binding with protein groups and inhibiting in this way glycosylation. Screening in vitro experiments with nicotinic acid, nicotinamide, piracetam, panangin, ascorbic acid, bucarban, betanase, and adebit in a concentration of 10(-3) M were performed. Bucarban, betanase, and adebit were found to be capable of inhibiting glycosylation. Daily oral administration of bucarban and adebit in therapeutic doses for one month reduced the blood fructosamine level in rats with alloxan diabetes without changing the level of glycemia.
Lebedeva
E A
EA
D000818:Animals; D001645:Biguanides / Q000494:pharmacology* / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D001798:Blood Proteins / Q000187:drug effects* / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D005260:Female; D019270:Fructosamine / Q000097:blood; D006031:Glycosylation / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D066298:In Vitro Techniques; D008297:Male; D051381:Rats; D012709:Serum Albumin / Q000187:drug effects / Q000378:metabolism; D013453:Sulfonylurea Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors
D001645:Biguanides; D001786:Blood Glucose; D001798:Blood Proteins; D007004:Hypoglycemic Agents; D012709:Serum Albumin; D013453:Sulfonylurea Compounds; D019270:Fructosamine